Impact of psychiatric disorders on the quality of life of brazilian HCV-infected patients by Batista-Neves, Susana et al.
www.bjid.com.br
4 0
Received on 7 June 2008; revised 11 December 2008.
Address for correspondence: Dr. Lucas C. Quarantini: Hospital Universitário
Professor Edgard Santos- Serviço de Psiquiatria- 3° andar. Rua Dr. Augusto
Viana S/N. Zip code: 40110-909 – Salvador – BA – Brazil. Phone: 55-71-
3332-3509 / Fax: 55-11-3332 3509. E-mail: lcq@ufba.br.
The Brazilian Journal of Infectious Diseases            2009;13(1):40-43.
© 2009 by The Brazilian Journal of Infectious Diseases and Contexto
Publishing. All rights reserved.
Impact of Psychiatric Disorders on the Quality of Life of Brazilian HCV-Infected Patients
Susana Batista-Neves1, Lucas C. Quarantini1,2, Amanda Galvão-de Almeida1, Maurício Cardeal1, Acioly L. Lacerda2, Raymundo
Paraná3, Irismar Reis de-Oliveira1, Rodrigo A. Bressan2 and Angela Miranda-Scippa1
1Federal University of Bahia - Hospital Universitário; 2Federal University of São Paulo - Laboratório Interdisciplinar de Neurociências Clínicas
(LiNC); São Paulo, SP, Brazil; 3Federal University of Bahia - Hospital Universitário - Unidade de Hepatologia; Salvador, BA, Brazil
The aim of our study was to determine the impact of psychiatric comorbidities on the health-related quality of life
of HCV-infected patients. Assessment of clinical, socio-demographic and quality of life data of the patients followed
up at a Hepatology unit was performed by using a standard questionnaire and the SF-36 instrument. Psychiatric
diagnoses were confirmed by using the Mini International Neuropsychiatric Interview, Brazilian version 5.0.0
(MINI Plus). Evaluation using the MINI plus demonstrated that 46 (51%) patients did not have any psychiatric
diagnosis, while 44 (49%) had at least one psychiatric diagnosis. Among patients with a psychiatric comorbidity, 26
(59.1%) had a current mental disorder, out of which 22 (84.6%) had not been previously diagnosed. Patients with
psychiatric disorders had lower scores in all dimensions of the SF-36 when compared to those who had no psychiatric
diagnosis. Scores of physical functioning and bodily pain domains were lower for those suffering from a current
psychiatric disorder when compared to those who had had a psychiatric disorder in the past. Females had lower
scores of bodily pain and mental health dimensions when compared to males. Scores for mental health dimension
were also lower for patients with advanced fibrosis. The presence of a psychiatric comorbidity was the variable that
was most associated with the different scores in the SF-36, compared to other variables such as age, gender,
aminotransferase levels, and degree of fibrosis.
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Hepatitis C virus (HCV) infection is a public health
problem throughout the world.  In Brazil, its prevalence is
estimated to be 2.5%-4.0% of the general population [1].
This disease progresses slowly and evolves into chronic
infection in 85% of the cases, of which 20 to 30% may develop
liver cirrhosis [2].
Different studies have reported impairment in health-
related quality of life (HRQOL) in patients with chronic
hepatitis C (CHC) infection, when compared to the general
population [3-5]. Factors such as presence of clinical
comorbidities, including psychiatric ones, stage of liver
disease, awareness of diagnosis and neurocognitive
alterations, have been associated with this impairment,
although there is no consensus as to what is the main
determinant of the decrease in HRQOL among these patients
[6-12]. The majority of the studies concerning HRQOL of
patients with HCV infection have not investigated psychiatric
comorbidities nor do they adequately measure the impact of
such an association [13]. Some of them merely evaluate
depression and anxiety symptoms by using self-rating
instruments, or seek out this information in medical files on
the patient’s chart, which may not accurately reflect the mental
state of these patients [5,8,14].
The objective of our study was to determine the impact of
psychiatric comorbidities on the HRQOL of HCV-infected
patients.
Material and Method
Participants
Patients were included if they tested positive for anti-HCV
antibody by the ELISA III method (Abbott, Chicago, IL),
confirmed by qualitative and/or quantitative determination of
HCV-RNA by AMPLICOR (Roche, Basel). The exclusion
criteria were: current or previous treatment with interferon
(IFN) during the previous three months, presence of non-
psychiatric comorbidity such as hypertension, diabetes
mellitus, hypothyroidism, or other medical conditions with
systemic repercussion, current use of propranolol or other
drugs associated with an increased risk of psychiatric
symptoms, cirrhosis classified as Child Pugh B and C or liver
disease decompensation. This study was done in accordance
with the Declaration of Helsinki and was approved by the
local Institutional Review Board. Written informed consent
was obtained from each patient.
Procedures
Assessment of clinical and socio-demographic data was
performed by using a standard questionnaire; we also
included aminotransferase levels from the last measurement
recorded on the chart and the degree of fibrosis as measured
by hepatic biopsy, according to METAVIR classification [15].
Psychiatric diagnoses were confirmed by using a Brazilian
version of the Mini International Neuropsychiatric Interview,
5.0.0 (MINI Plus) [16], consisting of a brief standardized
diagnostic interview that encompasses the main axis I
disorders of the Diagnostic and Statistical Manual of Mental
Disorders (DSM IV- American Psychiatric Association, 1994)
and the International Classification of Diseases (ICD-10-
World Health Organization-WHO, 1992). Before using MINI
Plus, a reliability study with two interviewers (LCQ, SB-N)
was performed.
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HRQOL was evaluated by using the Medical Outcomes
Study 36-Item Short-Form Health Survey (SF-36), which is a
self-administered as well as a generic instrument, previously
validated in Portuguese [17]. The SF-36 is composed of 36
items divided into eight dimensions: physical functioning,
physical role, bodily pain, general health, vitality, social
functioning, emotional role and mental health. Scores in each
dimension vary from zero to 100, representing the worst and
the best state of health, respectively.
Data Analysis
       The data were entered into EPIDATA software version
3.1 and analyzed with the R Package program version 2.3.1.
[18,19]. The measurements of epidemiological occurrence and
association were calculated, as well as the 95% confidence
interval, prevalence and prevalence rate. Analysis of parametric
variance was performed in order to investigate the joint
contribution of predictor variables in explaining the variability
of each dimension. The Student’s t-test for independent
samples and the Mann-Whitney test were used to compare
the groups of the study in relation to each dimension.
Results
In this cross-sectional study, 95 consecutive outpatients
with CHC from the University Hospital Liver Unit provided
written informed consent. Five of these later declined and
removed consent. The final study sample consisted of 90
individuals. Their ages ranged from 20 to 64, with a median of
45 years. Of these, 50 (55.5%) were male and 40 (44.4%) were
female. The majority of the patients were married (58.9%).
Thirty percent of HCV-infection transmission was through
blood transfusions; other means of infection included razor
blades, dental procedures, vitamin complex injections (14.4
%), use of injected drugs (8.9%), and tattooing (2.2%), while
44.4% did not know the means of infection (Table 1).
Aminotransferase levels were altered in 59 (65.5 %) of the
patients with CHC infection and 30 (33.3%) presented
persistently normal rates. Forty-nine (54.5%) patients were
submitted to biopsy, nine of them (18.4%) presented fibrosis
stage 1; 24 (49%) presented fibrosis stage 2; 12 (24.5%)
presented stage 3; and four (8.2%) demonstrated cirrhosis. 
The majority of the patients (77 - 85.5%), had no prior antiviral
treatment, while 13 (14.4%) had been treated more than three
months before. Fifty (55.5%) had HCV genotype 1 and 20
(22.2%) had genotypes 2 and 3 (Table 2).         
Evaluation using MINI plus demonstrated that 46 (51%)
patients did not have any psychiatric diagnosis while 44 (49%)
had at least one psychiatric diagnosis.  Among those with a
psychiatric comorbidity, 16 (36.4%) had two or more
psychiatric diagnoses.  The frequency found was: 26 (28.9%)
with alcohol and other substance abuse or dependence, 17
(18.9%) with mood disorders and 14 (15.6%) with anxiety
disorders. Among patients with a psychiatric comorbidity, 26
(59.1%) had a current mental disorder, out of which 22 (84.6%)
had not been previously diagnosed.
Patients whose aminotransferase levels were elevated had
53% more psychiatric disorders than those with normal
aminotransferase levels; though this difference was not
significant (p > 0.05). The presence of advanced fibrosis (stage
3 or 4), prior treatment, age ≥ 40 years or female gender did not
have a significant association with psychiatric disorders.
Patients with psychiatric disorders (past and current) had lower
scores in all of the eight dimensions of the SF-36, when
compared to those who had no psychiatric diagnosis (p <
0.05, Figure 1). Scores of physical functioning and bodily pain
domains were lower for those suffering from a current
psychiatric disorder when compared to those who had had a
psychiatric disorder in the past (p < 0.05, Figure 2).  Females
had lower scores of bodily pain and mental health dimensions
when compared to their male counterparts (p < 0.05). Scores
for mental health dimension were also lower for patients with
advanced fibrosis (p < 0.05).
Discussion
We found that psychiatric comorbidity was the variable
that was most associated with the different scores on the SF-
36, compared to other variables such as age, gender,
aminotransferase levels, and degree of fibrosis.
Additionally, patients with a current psychiatric
comorbidity had lower scores in only two dimensions
(physical functioning and bodily pain), when compared to
those who had experienced psychiatric morbidity in the past. 
This result is difficult to explain because having a current
disorder could be associated with greater loss in all
dimensions, since psychiatric symptoms can worsen HRQOL,
as reported in other studies [14,20].
Other authors who have also used a standardized
diagnostic interview have demonstrated that depression is
associated with low SF-36 scores; although in these studies
HCV-infected patients undergoing treatment with IFN were
not excluded, which could have interfered negatively in the
assessment of HRQOL and increased the incidence of
psychiatric events [21-24].
Similar to most previously-published studies, the liver
aminotransferase levels were not related to SF-36 scores,
perhaps because they were not associated with increased
rates of psychiatric comorbidity [5,8,9,25-27]. Patients with
CHC that presented more advanced fibrosis (stage 3 and
4) did not differ in their SF-36 scores, except in the
dimension of mental health, in comparison to those who
presented less advanced fibrosis (stage 1 and 2). Most
studies have not demonstrated an association between
stage of fibrosis and quality of life, except in cases of
advanced cirrhosis [3,8,9,14,20,28,29]. In our study, only
54.5% were submitted to a biopsy and only four of them
(8.2%) had cirrhosis. Furthermore, the small number of
intravenous drug users is consistent with previous reports
regarding the route of infection in Brazil [21,30,31].
Therefore, it may not be possible to generalize these results
to our population.
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In conclusion, our data suggest that a psychiatric
comorbidity is an important factor influencing quality of life
among HCV-infected patients. Further investigations with
larger sample sizes are necessary to provide better information
to confirm our findings.
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Table 3. Association between psychiatric disorders and clinical-demographic characteristics of chronic hepatitis C patients,
Bahia, Brazil.
 Psychiatric disorders PR 95% CI
Aminotransferase   
Elevated rates 55.9% 1.53 [0.91-2.57]
Normal rates 36.7%
Fibrosis
Stage 3 or 4 62.5% 1.15 [0.70-1.87]
Stage 1 or 2 54.5%
Prior Treatment
Yes 61.5% 1.32 [0.81-2.15]
No 46.8%
Gender
Female 47.5% 0.95 [0.62-1.43]
Male 50.0%
Age
 ≥ 40 years 51.4% 1.29 [0.72-2.30]
< 40 years 40.0%
  
PR= prevalence rate. CI= confidence interval.
